share_log
Reuters ·  Mar 19 11:00
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated With Bb-301 in Phase 1B/2a Study to Be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 279

Recommended

Write a comment